Strategies targeting tumor immune and stromal microenvironment and their clinical relevance

[Display omitted] The critical role of tumor microenvironment (TME) in tumor initiation and development has been well-recognized after more than a century of studies. Numerous therapeutic approaches targeting TME are rapidly developed including those leveraging nanotechnology, which have been furthe...

Full description

Saved in:
Bibliographic Details
Published in:Advanced drug delivery reviews 2022-04, Vol.183, p.114137-114137, Article 114137
Main Authors: Hu, Mengying, Huang, Leaf
Format: Article
Language:English
Subjects:
Animals
Clinical development
Drug Delivery Systems
Humans
Nanomedicine
Nanoparticles
Nanotechnology
Neoplasms - drug therapy
Neoplasms - pathology
Tumor Microenvironment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[Display omitted] The critical role of tumor microenvironment (TME) in tumor initiation and development has been well-recognized after more than a century of studies. Numerous therapeutic approaches targeting TME are rapidly developed including those leveraging nanotechnology, which have been further accelerated since the emergence of immune checkpoint blockade therapies in the past decade. While there are many reviews focusing on TME remodeling therapies via drug delivery and engineering strategies in animal models, state-of-the-art evaluation of clinical development states of TME-targeted therapeutics is rarely found. Here, we illustrate opportunities for integrating nano-delivery system for the development of TME-specific therapeutic regimen, followed by a comprehensive summary of the most up to date approved or clinically evaluated therapeutics targeting cellular and extracellular components within tumor immune and stromal microenvironment, including small molecule and monoclonal antibody drugs as well as nanomedicines. In the end, we also discuss challenges and possible solutions for clinical translation of TME-targeted nanomedicines.
ISSN:0169-409X
1872-8294
DOI:10.1016/j.addr.2022.114137